Q&A. How does the conflict between UA & RU impact the pharma industry?

Webinar: How does the conflict between UA & RU impact the pharma industry?

Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And with good reason. Russia’s invasion of Ukraine affects millions of people, not just in this Eastern European nation but throughout the world. From delays throughout development, loss of business continuity, and risk of non-compliance for on-market products, there are many affected areas.

Trying to adapt to the situation?

Let’s talk how we can work together to adapt your strategy.

Who Should Attend?

Professionals from the following fields:

  • Clinical Research
  • Regulatory Affairs
  • Pharmacovigilance
  • Medical Information
  • Quality Assuranc

Duration: 55 min.

Speakers:

  • Regina Auškalnienė, Chief Global Clinical Research Officer
  • Martijn van de Leur, Head of Global Pharmacovigilance
  • Saulenė Kudarauskaitė, Quality Assurance Manager.
Regina Auškalnienė

Regina Auškalnienė

Chief Global Clinical Research Officer

Other content that might interest you:

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Running a Clinical Trial in Ukraine

Running a Clinical Trial in Ukraine

Despite the fact that Ukraine is the largest country in Eastern Europe with a large population of treatment-naïve patients, well organized public health care sector and significant number of medical sites accredited for clinical trial conduction, country has utilized only 15% of its current potential for hosting clinical trials. During 2017, the European Medicine Agency (EMA) gave positive recommendations on 94 new drug applications and 49 of them were tested in clinical trials in Ukraine. During the same year, the US FDA approved 151 new drugs, and 28 of them were also studied in Ukraine.

read more
What You Need to Know about Running a Clinical Trial in Russia?

What You Need to Know about Running a Clinical Trial in Russia?

Russia is a very perspective country for international clinical trial conduction. The first international clinical trial was set up in Russia about 20 years ago only, and from than country kept a great potential for market development. In 2018 health authorities (HAs) approved 653 clinical trials (CT) in Russian Federation, less in overall numbers compared to the same indicator from 2016 – 898 approved CTs. However, this decrease was observed across all types of clinical trials except for international multicentre clinical trials (IMCT).

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information